Accra has turned down a proposed health agreement with Washington over concerns about access to medical records, pathogen information, and restrictions on drug oversight. The decision has ignited a wider conversation about Africa’s health sovereignty and what happens next.
The rejection and its immediate fallout
The Ghanaian government has declined a new health partnership proposed by the United States, which would have provided around $109 million in American funding over five years. The overall program was valued at roughly $300 million, including expected complementary contributions from Ghana.
President John Dramani Mahama confirmed and explained the rejection during an appearance at the Council on Foreign Relations in New York on September 25. His words resonated widely.
What Washington was actually asking for
According to President Mahama, the draft agreement included provisions for transferring Ghana’s pathogen profiles and medical data to the United States. He also stated that the text imposed a counterpart funding requirement on Ghana and contained clauses regarding control over medical products entering the country.
For Mahama, these conditions were simply “humiliating.”
The specifics behind the refusal
The matter warrants a closer look beyond the striking rhetoric. Ghana did not reject a $100 million package merely because it came from the United States. The core issue lies in the conditions attached to the funding.
The Associated Press reported in May that the draft agreement, with a total value of about $300 million, would have brought Ghana approximately $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that some provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. According to him, the scope of this access went far beyond what is typically necessary.
The BMJ also reported that the Ghanaian draft envisioned access to health data and pathogens for 16 American companies. The journal noted, however, that several clauses of the new US health agreements remain difficult to examine publicly, as not all negotiated texts have been made public.
A nuance is therefore necessary: it would be excessive to claim that the United States was demanding unrestricted access to “all Ghanaians’ medical data.” What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.
Why these data matter so much
Behind medical records lies a genuine question of power. Health data reveal which diseases are circulating, where they are spreading, which populations are most exposed, and how epidemics are evolving.
Pathogen data can also have considerable scientific value. They can contribute to research on vaccines, treatments, and surveillance of emerging outbreaks. This is precisely what fuels concerns among several African governments.
In February 2026, Jean Kaseya, director general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already expressed serious concerns about provisions related to data and pathogen sharing in the new US health agreements. Reuters reported at the time that some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.
Ghana is therefore not an isolated case.
Accra’s push to reduce reliance on foreign aid
The rejection also occurs in a particular context. Since the suspension of a large portion of US aid programs, Ghana has sought to reduce its dependence on external funding. In February 2025, the Ghanaian presidency estimated the shortfall caused by the suspension of USAID funding at $156 million, of which $78.2 million directly affected essential health programs.
The Mahama government is now promoting the idea of “health sovereignty.” This direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes reducing Southern countries’ dependence on external funding and strengthening their own health systems.
Accra’s message is therefore relatively clear: Ghana wants to continue working with foreign partners, but on the basis of agreements it considers more balanced.
Another point of friction: medicines
The other element revealed by Mahama is particularly sensitive. According to the president, the draft agreement stipulated that certain medicines and medical products provided under the program would not be subject to controls by Ghana’s Food and Drugs Authority (FDA).
This claim has not been publicly confirmed in detail by the US government, which, when asked by the Associated Press, said it does not comment on the details of bilateral negotiations.
But if this provision indeed matched the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not lead to reducing the national regulator’s ability to control medical products used on its territory.
The American response
Washington has not publicly detailed the contested clauses. A US State Department spokesperson said the United States does not disclose details of bilateral negotiations, while affirming that Washington is still seeking ways to strengthen its partnership with Ghana.
This lack of full publication of the text prevents definitive answers to certain essential questions. Exactly what data would have been accessible? To which American companies or institutions? Under what circumstances could individuals have been identified? How long would data have been retained? What legal guarantees would have protected Ghanaian patients?
On these points, public information remains incomplete.
Ghana opens a debate that goes beyond its borders
The real issue in this affair may lie there. For decades, many African health systems have depended on funding, medicines, equipment, and programs from abroad. These partnerships have saved lives and fought major diseases.
But the digital transformation of health is now changing the nature of cooperation. Aid is no longer just about money, medicines, or equipment. It can also give access to a strategic resource: data.
And Ghana has just reminded everyone that it intends to retain control over that resource.
John Mahama asserts that his government rejected the draft after review by the Ministry of Health and its passage before the Cabinet. He also says the decision had the support of the entire government and that the rejection was decided very quickly.
Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programs. But for Accra, the choice seems deliberate: better to seek other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.
The question Ghana now poses to its foreign partners is simple: when Africa receives aid to care for its populations, must it also surrender control over information about those populations? The debate is probably only beginning.
